MedTrace Logo

Endovascular Treatment of Aorto-iliac Disease Using in Situ Fenestration

NCT04062734 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2025-03-18

No results posted yet for this study

Summary

In situ fenestration (ISF) could represent an alternative in the treatment of aorto-iliac disease when usual techniques are not available. The aim of this study was to present the results of ISF in aorto-iliac disease. Data will retrospectively be analyzed. Inclusion criteria will be: a surgical abdominal aortic aneurysm (AAA) with an unsuitable anatomy for a standard endograft, aorto-iliac occlusion with narrow distal aorta (\<14mm). Technically, after placement of the endograft, a transjugular intrahepatic access set was used to perform ISF. The hole was secondary enlarged using a cutting or non-compliant balloon. Finally, a kissing stent was performed to the aorto- uni-iliac into a bifurcated endograft.

Conditions

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Raphaël COSCAS, MD, PhD · Service de Chirurgie Vasculaire, Hôpital Ambroise Paré

  • Jérémie JAYET, MD · Service de Chirurgie Vasculaire, Hôpital Ambroise Paré

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-27
Primary Completion
2020-12-02
Completion
2020-12-02

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04062734 on ClinicalTrials.gov